share_log

BRIEF-AIM Immunotech Submits IND And Accompanying Fast Track Application For Phase 2 Trial Of Ampligen In Patients With Locally Advanced Or Metastatic Late-Stage Pancreatic Cancer

BRIEF-AIM Immunotech Submits IND And Accompanying Fast Track Application For Phase 2 Trial Of Ampligen In Patients With Locally Advanced Or Metastatic Late-Stage Pancreatic Cancer

Brief-AIM免疫技术提交Ind和伴随的Fast Track应用于局部晚期或转移性晚期胰腺癌患者的Ampligen第2期试验
reuters ·  2021/10/19 07:25

Oct 19 (Reuters) - AIM ImmunoTech Inc AIM.A :

路透10月19日电-AIM Immunotech Inc AIM.A:

* AIM IMMUNOTECH SUBMITS IND AND ACCOMPANYING FAST TRACK APPLICATION FOR PHASE 2 TRIAL OF AMPLIGEN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LATE-STAGE PANCREATIC CANCER

*AIM Immunotech提交Ind和随附的Fast Track申请,用于局部晚期或转移性晚期胰腺癌患者的Ampligen第2期试验

Source text for Eikon: ID:nGNEMYnyj Further company coverage: AIM.A

Eikon的源文本:ID:nGNEMYnyj进一步的公司报道:AIM.A

((reuters.briefs@thomsonreuters.com;))

(reurs.Briefs@thomsonreurs.com;)

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发